AQR Capital Management LLC Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AQR Capital Management LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 207,085 shares of the biopharmaceutical company's stock after selling 18,449 shares during the quarter. AQR Capital Management LLC owned 0.19% of Regeneron Pharmaceuticals worth $147,096,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Willner & Heller LLC grew its position in Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock valued at $284,000 after acquiring an additional 15 shares during the last quarter. OLD Second National Bank of Aurora increased its position in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock worth $2,025,000 after purchasing an additional 15 shares in the last quarter. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. TD Private Client Wealth LLC lifted its stake in Regeneron Pharmaceuticals by 9.6% in the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after purchasing an additional 15 shares during the last quarter. Finally, Manchester Capital Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 12.6% during the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock worth $115,000 after buying an additional 18 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 2.6 %

Shares of REGN stock traded up $15.61 on Friday, hitting $605.61. The stock had a trading volume of 1,606,415 shares, compared to its average volume of 744,231. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The business has a 50 day moving average of $626.49 and a 200 day moving average of $711.45. Regeneron Pharmaceuticals, Inc. has a 12-month low of $525.99 and a 12-month high of $1,211.20. The stock has a market cap of $66.21 billion, a price-to-earnings ratio of 15.82, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same period in the previous year, the business posted $9.55 earnings per share. The business's revenue was down 3.7% compared to the same quarter last year. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating on the stock in a research note on Wednesday. Bank of America cut their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a report on Thursday, April 17th. Robert W. Baird decreased their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. JPMorgan Chase & Co. reduced their price target on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a research report on Monday, March 31st. Finally, TD Cowen lowered their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, five have given a hold rating, eighteen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $892.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.